Selective FGFR targeting is intended to lessen side effects, whereas the dual targeting of VEGFR/CSF1R and FGFR is predicted to increase anti-tumor effects indirectly by normalizing the TME [116]. The gene discussed is KDR; the disease is neoplasm.